💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Amenamevir

CHEMBL4297592 Phase 4 承認済み Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
482.6 g/mol
LogP
2.6
Phase
4

Herpesvirus replication requires a helicase-primase complex to unwind and prime viral DNA, and amenamevir was designed to inhibit that complex. This places it outside the nucleoside-analogue class represented by acyclovir, which instead depends on viral thymidine kinase activation and chain termination. The mechanistic separation matters clinically, since it offers a route to activity against herpesvirus strains that have become resistant to nucleoside analogues. Approval in Japan covers herpes zoster, the reactivation syndrome caused by varicella-zoster virus. Structurally the agent is a small molecule with the formula C24H26N4O5S and a molecular weight of roughly 482.6 g/mol, and it has reached the final phase of clinical development.

An antiviral medication that inhibits the helicase-primase enzyme complex essential for herpesvirus DNA replication, offering a different mechanism of action from nucleoside analogues like acyclovir. It is approved in Japan for treating herpes zoster (shingles) and may be effective in patients with acyclovir-resistant herpesvirus infections.

分子量

482.6000 g/mol

LogP

2.60

TPSA

131.00 Ų

リピンスキーの五則

適合

治療領域

Infectious Disease

作用機序

A helicase-primase inhibitor. Amenamevir binds the herpesvirus helicase-primase complex, blocking both the unwinding of double-stranded viral DNA and the synthesis of the RNA primers needed to start replication. Because the mechanism does not depend on viral thymidine kinase activation, it remains active against strains resistant to nucleoside analogues such as acyclovir.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

A helicase-primase inhibitor. Amenamevir binds the herpesvirus helicase-primase complex, blocking both the unwinding of double-stranded viral DNA and the synthesis of the RNA primers needed to start replication. Because the …

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1cccc(C)c1N(CC(=O)Nc1ccc(-c2ncon2)cc1)C(=O)C1CCS(=O)(=O)CC1

                

                

                
                

                    
InChI

                    
InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)

                

                

                

                    
                    

                        
Molecular Formula

                        
C24H26N4O5S

                    

                    
                    

                        
HBD / HBA

                        
1 / 7

                    

                    
                    

                        
回転可能結合数

                        
6

                    

                    
                    
                    

                        
重原子数

                        
34

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
An antiviral medication that inhibits the helicase-primase enzyme complex essential for herpesvirus DNA replication, offering a different mechanism of action from nucleoside analogues like acyclovir. It is approved in Japan for treating herpes zoster (shingles) and may be effective in patients with acyclovir-resistant herpesvirus infections.

                        

                    

                    

                    

                    
                    

                        
                        

                            
A helicase-primase inhibitor. Amenamevir binds the herpesvirus helicase-primase complex, blocking both the unwinding of double-stranded viral DNA and the synthesis of the RNA primers needed to start replication. Because the mechanism does not depend on viral thymidine kinase activation, it remains active against strains resistant to nucleoside analogues such as acyclovir.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Amenamevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4297592.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 11397521.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.